Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications. The data from the SLE model will be presented in an oral presentation at the American Association of Immunologists (AAI) meeting in Boston, Massachusetts at 8:00a.m. ET on May 5, 2012. The oral presentation, entitled "IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice," will be made during the session "Therapeutic Strategies for Rheumatologic Diseases."    

Idera expects to submit to the FDA an Investigational New Drug application for IMO-8400 during the fourth quarter of 2012, and has selected lupus as the initial disease indication for clinical development.

In addition to the oral presentation, a poster presentation entitled "IMO-8400, a novel TLR7, TLR8, and TLR9 antagonist, inhibits disease development in mouse models of psoriasis" is scheduled for May 6, 2012, in the session "Novel and Cellular Approaches to Autoimmunity" during AAI.

Source: Idera Pharmaceuticals, Inc.